Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy

Vaccine

Volumn 18, Issue 18, 2000, Pages 1952-1961

  Lee, Na Gyong ^a   Jung, Sang Bo ^a   Ahn, Bo Young ^a   Kim, Young Hoon ^a   Kim, Jeong Jin ^b   Kim, Dong Kun ^b   Kim, Ik Sang ^c   Yoon, Suk Min ^a   Nam, Sung Woo ^a   Kim, Hyun Su ^a   Park, Wan Je ^a  

^a R and D Center of Bioscience   (South Korea)

^b Hallym University   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Burn patients; P. aeruginosa outer membrane protein vaccine; Protective antibody

Indexed keywords

ANTIBODY; OUTER MEMBRANE PROTEIN; PSEUDOMONAS VACCINE;

ACTIVE IMMUNIZATION; ARTICLE; BURN; CONTROLLED STUDY; DRUG EFFICACY; GRAM NEGATIVE INFECTION; HUMAN; IMMUNOBLOTTING; IMMUNOPRECIPITATION; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SURVIVAL;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGEN-ANTIBODY REACTIONS; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; BURNS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED ICR; OPSONIN PROTEINS; PHAGOCYTOSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RABBITS; VACCINES, INACTIVATED;

EID: 0343502992     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00479-X     Document Type: Article

References (42)

1. Pruitt B.A. Jr, Colonel M.C., McManus A.T. Opportunistic infections in severely burned patients. American Journal of Medicine. 30:1984;146-154.
2. McManus A.T., Mason A.D. Jr, McManus W.F., Pruitt B.A. Jr. Twenty-five year review of Pseudomonas aeruginosa bacteremia in a burn center. European Journal of Clinical Microbiology. 4:(2):1985;219-223.
3. Kolmos H.J., Thuesen B., Nielsen S.V., Lohmann M., Kristoffersen K., Rosdahl V.T. Outbreak of infection in a burns unit due to Pseudomonas aeruginosa originating from contaminated tubing used for irrigation of patients. Journal of Hospital Infection. 24:(1):1993;11-21.
4. Korvick J.A., Marsh J.W., Starzl T.E., Yu V.L. Pseudomonas aeruginosa bacteremia in patients undergoing liver transplantation: an emerging problem. Surgery. 109:(1):1991;62-68.
5. Spencer R.C. Predominant pathogens found in the European prevalence of infection in intensive care study. European Journal of Clinical Microbiology and Infectious Diseases. 15:(4):1996;281-285.
6. Velasco E., Thuler L.C., Martins C.A., Dias L.M., Goncalves V.M. Nosocomial infections in an oncology intensive care unit. American Journal of Infection Control. 25:(6):1997;458-462.
7. Høiby N., Schiotz O. Immune complex mediated tissue damage in the lungs of CF patients with chronic Pseudomonas aeruginosa infection. Warwick W. 1000 years of cystic fibrosis. 1981;147-157 University of Minnesota Press, Minneapolis.
8. Hancock R.E. Intrinsic antibiotic resistance of Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy. 18:(6):1986;653-656.
9. Richard P., Le Floch R., Chamoux C., Pannier M., Espaze E., Richet H. Pseudomonas aeruginosa outbreak in a burn unit: role of antimicrobials in the emergence of multiply resistant strains. Journal of Infectious Diseases. 170:(2):1994;377-383.
10. Hsueh P.R., Teng L.J., Yang P.C., Chen Y.C., Ho S.W., Luh K.T. Persistence of a multidrug-resistant Pseudomonas aeruginosa clone in an intensive care burn unit. Journal of Clinical Microbiology. 36:(5):1998;1347-1351.
11. Jones R.J., Roe E.A., Gupta J.L. Controlled trials of a polyvalent pseudomonas vaccine in burns. Lancet. 2:(8150):1979;977-982.
12. Roe E.A., Jones R.J. Immunization of burned patients against Pseudomonas aeruginosa infection at Safdarjang hospital, New Delhi. Review of Infectious Diseases. 5:(Suppl. 5):1983;S922-S930.
13. Cryz S.J. Jr, Furer E., Cross A.S., Wegmann A., Germanier R., Sadoff J.C. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans. Journal of Clinical Investigation. 80:(1):1987;51-56.
14. Schaad U.B., Lang A.B., Wedgwood J., et al. Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis. Lancet. 338:(8777):1991;1236-1237.
15. Lang A.B., Schaad U.B., Rudeberg A., et al. Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Journal of Pediatrics. 127:1995;711-717.
16. Pier G.B., Desjardin D., Grout M., et al. Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine. Infection and Immunity. 62:(9):1994;3972-3979.
17. von Specht B.-U., Lucking H.C., Blum B., Schmitt A., Hungerer K.D., Domdey H. Safety and immunogenicity of a Pseudomonas aeruginosa outer membrane protein I vaccine in human volunteers. Vaccine. 14:(12):1996;1111-1117.
18. Mansouri E., Gabelsberger J., Knapp B., et al. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Infection and Immunity. 67:(3):1999;1461-1470.
19. Park W.J., Cho Y.-J., Ahn D.H., et al. An outer membrane protein preparation as a vaccine against Pseudomonas aeruginosa infection. Journal of Microbiology and Biotechnology. 7:(2):1997;144-150.
20. Park W.J., Cho Y.J., Kim Y.G., et al. Active and passive protective effect of CFC-101 (Pseudomonas vaccine) in mice. Journal of Applied Pharmacology. 2:1994;326-330.
21. Jang I.-J., Kim I.-S., Park W.J., et al. Human immune response to a Pseudomonas aeruginosa outer membrane protein vaccine. Vaccine. 17:(2):1999;158-168.
22. Mousa H.A. Aerobic, anaerobic and fungal burn wound infections. Journal of Hospital Infection. 37:(4):1997;317-323.
23. Arturson G., Hogman C.F., Johansson S.G., Killander J. Changes in immunoglobulin levels in severely burned patients. Lancet. 1:(7594):1969;546-548.
24. Alexander J.W., Meakins J.L. A physiological basis for the development of opportunistic infections in man. Annals of Surgery. 176:(3):1972;273-287.
25. Fujimaki K., Noumi T., Saikawa I., Inoue M., Mitsuhashi S. In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone. Antimicrobial Agents and Chemotherapy. 32:(6):1988;827-833.
26. Lee N.-G., Jung S.B., Ahn B.-Y., et al. Protection of mice against P. aeruginosa infections by large-scale affinity-purified human IgG specific to P. aeruginosa outer membrane proteins. Vaccine. 18:2000;665-674.
27. Apicella M.A., Griffiss J.M., Schneider H. Isolation and characterization of lipopolysaccharides, lipooligosaccharides, and lipid A. Methods in Enzymology. 235:1994;242-252.
28. Gilleland H.E. Jr, Parker M.G., Matthews-Greer J.M., Berg R.D. Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice. Infection and Immunity. 44:(1):1984;49-54.
29. Lee N.-G., Ahn B.-Y., Jung S.B., et al. Human anti-Pseudomonas aeruginosa outer membrane proteins IgG cross-protective against infection with heterologous immunotype strains of P. aeruginosa. FEMS Immunology and Medical Microbiology. 25:(4):1999;339-347.
30. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of National Cancer Institute. 22:1959;719-748.
31. Hancock R.E., Carey A.M. Outer membrane of Pseudomonas aeruginosa: heat- and 2-mercaptoethanol-modifiable proteins. Journal of Bacteriology. 140:(3):1979;902-910.
32. Matthews-Greer J.M., Gilleland H.E. Jr. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model. Journal of Infectious Diseases. 155:(6):1987;1282-1291.
33. Bjornson A.B., Alexander J.W. Alterations of serum opsonins in patients with severe thermal injury. Journal of Laboratory Clinical Medicine. 83:(3):1974;372-382.
34. Ono Y., Kunii O., Suzuki H., Ikeda H., Kobayashi K., Kanegasaki S. Opsonic activity of sera and blister fluid from severely burned patients evaluated by a chemiluminescence method. Microbiology and Immunology. 38:(5):1994;373-377.
35. Burleson D.G., Mason A.D., Pruitt B.A. Jr. Lymphoid subpopulation changes after thermal injury and thermal injury with infection in an experimental model. Annals of Surgery. 207:1988;208-212.
36. Zedler S., Faist E., Ostermeier B., von Donnersmarck G.H., Schildberg F.W. Postburn constitutional changes in T-cell reactivity occur in CD8+ rather than in CD4+ cells. Journal of Trauma. 42:(5):1997;872-880.
37. Lawrence M.H., de Riesthal H.F., Calvano S.E. Changes in memory and naive CD4+ lymphocytes in lymph nodes and spleen after thermal injury. Journal of Burn Care and Rehabilitation. 17:(1):1996;1-6.
38. Bjornson A.B., Michael J.G. Factors in normal human serum that promote bacterial phagocytosis. Journal of Infectious Diseases. 128:(Suppl.):1973;S182-S186.
39. Bruderer U., Cryz S.J. Jr, Schaad U.B., Deusinger M., Que J.U., Lang A.B. Affinity constants of naturally acquired and vaccine-induced anti-Pseudomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients. Journal of Infectious Diseases. 166:(2):1992;344-349.
40. Lang A.B., Schaad U.B., Rudeberg A., et al. Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Journal of Pediatrics. 127:(5):1995;711-717.
41. Lee N-G, Ahn B-Y, Jung SB, Kim YG, Kim H-S, Park WJ. Conformation-dependent antibody response to Pseudomonas aeruginosa outer membrane proteins induced by immunization in humans. FEMS Immunology and Medical Microbiology (in press).
42. Muthania L.M., Nicas T.I., Hancock R.E. Outer membrane proteins of Pseudomonas aeruginosa serotype strains. Journal of Infectious Diseases. 146:(6):1982;770-779.